On persuading Novartis

Sergio Dompè, the president of the association of pharmaceutical industry (Farmindustria), hopes that Novartis and the Italian government will reach a new agreement to change their contract and to convert the swine flu vaccine supply in something else. Instead of buying other doses, the government will buy other products. Dompè said that, considering the actual need, it's understandable to find a way to make more efficient the expenditure (184 million euros). He also added that he will try to persuade Novartis to change the contract. Only 865,000 people in Italy got the swine flu shot, while some 10 millions of doses are stocked. Other 14 millions of doses have been ordered but not yet delivered.

Too late, too much

Today the Minister of Health, Professor Ferruccio Fazio, was asked in Parliament what to do with the unused doses of the swine flu vaccine. He was also questioned about the safety and efficacy of the vaccine itself, and about the costs of the campaign. Professor Fazio admitted that “the vaccine was available only when the first wave of the epidemic has begun”, and that the flu was, “thankfully”, really mild. These two facts have kept people away from the vaccine. Some 850,000 people got vaccinated, using a small fraction of the 10-million available doses. But there is this lesson of the swine flu, the vaccine supply was too late.

The Government expect to pay 184 million euros for 24 millions of doses, but the final figure could be less than that. According to the Minister, “the Government is evaluating some possibilities that could guarantee an appropriate use of the commitments decided by the Government against the swine flu.” The pronouncement isn't very clear, but it could mean the Government is going to sell the vaccine stock.

Swine flu lesson

"And if the virus were only a cold?" wrote La Repubblica some days ago. The article by Angelo Aquaro explains that the mortality of the swine flu has been by far inferior to the expected (0.018%, less than the seasonal flu), there's been a decrease of the hospitalized cases in the United States and Europe (except France) in the days of the expected peak, many controversies on the vaccines (in Italy only the 14% of the health care workers have been immunized), and on the role of the Big Pharma and on WHO. Italy has bought 24 millions of doses of Novartis vaccine for 184,8 million of euros.
"If until now the things have gone better than what was expected, the merit is not surely of the vaccination campaign that has involved a low number of people" is reported to have said in the article Mauro Moroni, Director of Infectious Disease Department of Sacco Hospital, in Milan. "The culprits of the flop, says De Martino, "are also who refused to get the shot themselves, and I speak about my medical colleagues, and the citizens".
And at the end there's the conclution of Giovanni Rezza, Director of Infectious Disease Department of Istituto superiore di sanità in Rome. "The truth is that from this crisis we have learned two lessons. First, that the opposite extremisms, alarmism and denyingser, are counter-productive. The second one is that we must learn to produce the vaccine more quickly in order to prevent situations more serious."